Zentalis Pharmaceuticals, Inc. (ZNTL) has a negative trailing P/E of -1.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 95.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -57.41%, forward earnings yield 1.04%.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -19.9 | 0.00 | 16.91 | 29,924.69 | - |
| 2019 | -18.2 | -1.78 | 13.51 | 0.00 | - |
| 2020 | -18.1 | -0.15 | 6.91 | 0.00 | - |
| 2021 | -22.6 | -0.76 | 9.86 | 0.00 | - |
| 2022 | -4.5 | -0.22 | 2.45 | 0.00 | - |
| 2023 | -3.4 | 15.19 | 2.27 | 0.00 | - |
| 2024 | -1.3 | 0.03 | 0.64 | 3.19 | - |
| 2025 | -0.7 | 0.04 | 0.45 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-1.17 | $14K | $-21.07M | -150478.6% |
| 2019 | $-1.29 | $0.00 | $-46.38M | - |
| 2020 | $-2.89 | $0.00 | $-118.55M | - |
| 2021 | $-3.85 | $0.00 | $-164.26M | - |
| 2022 | $-4.48 | $0.00 | $-236.81M | - |
| 2023 | $-4.47 | $0.00 | $-292.19M | - |
| 2024 | $-2.33 | $67.43M | $-165.84M | -246% |
| 2025 | $-1.91 | $0.00 | $-137.06M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.05 | $-2.55 – $-1.41 | $2.14M | $1.03M – $2.97M | 6 |
| 2027 | $-1.63 | $-2.33 – $-1.02 | $22.58M | $10.84M – $31.26M | 6 |
| 2028 | $-1.51 | $-2.30 – $-0.49 | $71.64M | $70.52M – $72.77M | 6 |
| 2029 | $-0.57 | $-0.86 – $-0.19 | $186.77M | $89.64M – $258.54M | 4 |
| 2030 | $0.31 | $0.10 – $0.46 | $323.46M | $155.25M – $447.76M | 2 |
